

**Corp. Off.:** 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29<sup>th</sup> May, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today 29<sup>th</sup> May, 2019 has, inter alia, approved the Audited Financial Results of the Company for Quarter & Year ended 31<sup>st</sup> March, 2019.

Enclosed please find herewith the following

1. Audited financial results of the Company for the financial year ended 31<sup>st</sup> March, 2019 and the financial results of the Company in respect of the fourth quarter of FY 2018-19.
2. Statement of Assets and Liabilities.
3. The Auditors Report,
4. Declaration from the Company for Audit Report is of 'Unmodified Opinion',


The aforesaid result and report are attached for your record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

  
(Jyoti Sancheti)



Company Secretary cum Compliance Officer

Encl.: As above

**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net

Website: www.brookslabs.net


Tel No : +91 1795 654001/02/03, -

Fax No : +91 1795 236939

**Audited Financial Results for the Quarter and year ended 31st March, 2019**

(Rs. In Lakhs)

No	Particulars	Quarter Ended			Year Ended	Year Ended
		31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
		Audited	Un-Audited	Audited	Audited	Audited
<b>1</b>	<b>Income</b>					
	(a) Revenue from operations	1,515.56	1,509.79	1,451.61	5,503.01	5,690.42
	(b) Other Income	245.60	10.38	11.85	287.76	24.02
	<b>Total income</b>	<b>1,761.16</b>	<b>1,520.17</b>	<b>1,463.46</b>	<b>5,790.77</b>	<b>5,714.44</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	1,282.01	1,013.50	1,057.61	4,057.22	4,084.63
	(b) Change in inventories of finished goods, work-in-progress and stock-in-trade	(158.15)	(11.99)	(125.95)	(113.62)	(147.03)
	(c) Excise Duty on Sales	-	-	-	-	119.27
	(d) Employees benefits expenses	360.60	298.77	331.13	1,216.43	1,180.73
	(e) Finance Costs	72.29	76.90	72.42	296.26	240.43
	(f) Depreciation and amortization expenses	160.61	169.41	161.38	649.96	644.51
	(g) Other expenses	273.66	298.16	362.76	1,179.31	1,345.32
	<b>Total Expenses</b>	<b>1,991.02</b>	<b>1,844.75</b>	<b>1,859.35</b>	<b>7,285.56</b>	<b>7,467.86</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items and tax</b>	<b>(229.86)</b>	<b>(324.58)</b>	<b>(395.89)</b>	<b>(1,494.79)</b>	<b>(1,753.42)</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>(229.86)</b>	<b>(324.58)</b>	<b>(395.89)</b>	<b>(1,494.79)</b>	<b>(1,753.42)</b>
<b>6</b>	<b>Tax Expense:</b>					
	Current Tax	-	-	-	-	-
	Deferred Tax Liability / (Assets) (Refer Note no.8)	464.38	(109.98)	(169.65)	(14.48)	(375.09)
	Short income tax provision for earlier years	-	-	-	0.23	2.95
<b>7</b>	<b>Net Profit/(loss) after tax</b>	<b>(694.24)</b>	<b>(214.60)</b>	<b>(226.24)</b>	<b>(1,480.54)</b>	<b>(1,381.28)</b>
<b>8</b>	<b>Other Comprehensive Income</b>					
	<b>Items That will not be reclassified into Profit or loss</b>					
	Actuarial loss on Defined Benefit plans (net of tax).	(7.72)	0.20	0.78	(7.11)	0.81
<b>9</b>	<b>Total Comprehensive income for the period (After tax)</b>	<b>(701.96)</b>	<b>(214.40)</b>	<b>(225.46)</b>	<b>(1,487.63)</b>	<b>(1,380.47)</b>
<b>10</b>	<b>Paid - up equity share capital of Rs.10 each</b>	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
<b>11</b>	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	11,209.05	11,209.05	11,209.05	11,209.05	11,209.05
<b>12</b>	<b>Earnings per share of Rs.10/- each (not annualised):</b>					
	(a) Basic	(4.29)	(1.33)	(1.40)	(9.20)	(8.53)
	(b) Diluted	(4.29)	(1.33)	(1.40)	(9.20)	(8.53)





**Notes:**

- 1 The above audited financial results of the Company for quarter / year ended 31st March, 2019 have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on 29th March, 2019
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 During the quarter company has reversed deferred tax asset amounting to Rs.324.92 Lakhs on the unabsorbed losses in accordance to Ind AS 12 on "Income Taxes".
- 4 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS – 108 in this regard are not applicable.
- 5 In terms of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended ("ICDR Regulations"), the company upon the shareholders approval at the Annual General Meeting held on 10th August, 2018 issued and allotted 8,50,000 Convertible warrants, by circular resolution dated 6th September, 2018 and 14th September, 2018 at a conversion price of Rs. 95.50 per Equity share aggregating to Rs 8,11,75,000. The company has received Rs 2,61,49,000/- as upfront amount. Subsequently, Rs.2,94,00,000 has been received against balance amount of Convertible Warrants. These warrants will be converted into an equivalent number of Equity shares of face value Rs. 10 each at premium of Rs 85.50 per share, in the company, upon receipt of balance amount of Rs.2,56,26,000, within a period of 18 months from the date of allotment.
- 6 Comparative financial information of the previous quarter and financial year have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.
- 7 The figures of the last quarters ended March 31, 2019 and March 31, 2018 are the balancing figures between audited figures in respect of full financial years and the published year to date figures up to the third quarters of the respective financial years.

**For and on Behalf of Board**



**Rajesh Mahajan**  
**Din : 02000634**  
**Managing Director**

Place : Mumbai  
Date : 29th May 2019

**Brooks Laboratories Limited**  
Statement of Assets & Liabilities as at March 31, 2019


(Rs. In Lakhs)

Particulars	As at March 31, 2019	As at March 31, 2018
	Audited	Audited
<b>A ASSETS</b>		
<b>1 Non Current Assets</b>		
(a) Property, Plant and Equipment	11,717.18	12,401.04
(b) Capital work-in-progress	-	52.16
(c) Intangible asset	8.00	-
(d) Intangible asset under development	28.91	-
(d) Investment Property	63.35	63.35
(e) Financial assets		
(i) Investments	2.00	2.00
(ii) Other Financial Assets	148.19	140.75
(f) Income Tax Asset (Net)	495.19	438.92
(g) Deferred tax Asset (Net)	1,091.19	1,073.97
(h) Other Non Current Assets	44.80	25.05
<b>Total Non - Current Assets</b>	<b>13,598.81</b>	<b>14,197.24</b>
<b>2 Current assets</b>		
(a) Inventories	1,005.34	1,140.91
(b) Financial Assets		
(i) Trade receivables	1,141.70	1,018.24
(ii) Cash and Cash Equivalents	249.39	64.52
(iii) Bank Balances other than Cash & cash equivalents	97.38	131.95
(iv) Other Financial Assets	24.72	33.42
(c) Other Current Assets	677.75	680.44
<b>Total Current Assets</b>	<b>3,196.28</b>	<b>3,069.48</b>
<b>TOTAL ASSETS</b>	<b>16,795.09</b>	<b>17,266.73</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity Share Capital	1,618.64	1,618.64
(c) Other Equity (Refer Note No.6)	8,896.43	9,828.59
<b>Total Equity</b>	<b>10,515.07</b>	<b>11,447.23</b>
<b>Liabilities</b>		
<b>2 Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,386.39	1,663.00
(b) Provisions	147.52	108.42
<b>Total Non - Current Liabilities</b>	<b>1,533.91</b>	<b>1,771.42</b>
<b>3 Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,446.88	854.44
(ii) Trade Payables		
- Due to micro and small enterprises	302.96	76.68
- Due to Others	2,410.98	2,587.87
(iii) Other Financial Liabilities	433.77	401.82
(b) Other current liabilities	129.75	92.77
(c) Provisions	21.77	34.51
<b>Total Current Liabilities</b>	<b>4,746.11</b>	<b>4,048.09</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>16,795.09</b>	<b>17,266.73</b>

Place : Mumbai  
Date : 29th May 2019

For Brooks Laboratories Limited

Rajesh Mahajan  
Din : 02000634  
Managing Director





# **SGCO & Co.LLP**

**Chartered Accountants**

**Independent Auditor's Report on Annual Financial Results of Brooks Laboratories Limited for the quarter and year ended March 31, 2019 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Brooks Laboratories Limited

1. We have audited the accompanying financial results ('the Statement') of Brooks Laboratories Limited ('the Company') for the quarter and year ended 31<sup>st</sup> March, 2019 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/ 6212016 dated July 5<sup>th</sup>, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This Statement has been prepared on the basis of Annual financial statements. Our responsibility is to express an opinion on this Statement, based on our audit of such Annual Financial Statements, which have been prepared in accordance with the Accounting Standards specified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 7 of the Companies (Account) Rules, 2014 and other accounting principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the annual financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.
3. We believe that the audit evidences obtained by us is sufficient and appropriate to provide a reasonable basis for our opinion on the statement.
4. In our opinion and to the best of our information and according to the explanations given to us, these annual financial results:
  - a. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard
  - b. give a true and fair view of the net loss, total comprehensive loss and other financial information for the year ended March 31, 2019.

4A, Kaledonia,  
2<sup>nd</sup> Floor, Sahar Road,  
Near: Andheri Station,  
Andheri (East),  
Mumbai - 400 069.

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail: info@sgco.co.in  
www.sgco.co.in



Mumbai • Delhi



# **SGCO & Co.LLP**

**Chartered Accountants**

5. The statement includes the results for the quarter ended 31<sup>st</sup> March 2019, being the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For S G C O & Co. LLP**

Chartered Accountants

**Firm's Registration No. 112081W/W100184**

  
**Suresh Murarka**

Partner

**Mem No. 044739**

Place : Mumbai

Date : 29<sup>th</sup> May 2019



**Corp. Off.:** 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29<sup>th</sup> May, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

**Sub: Declaration by the Company for Auditors Unmodified opinion on the Audited Financials Results for the year ended 2018-19**

Dear Sirs,

This has reference to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016 regarding disclosure of the Impact of Audit Qualifications by the Listed Companies.

We hereby declare that the Audit Report for the Annual Audited Financial Results for the year ended 31.03.2019 is of '**Unmodified Opinion**'.

Kindly take the same on record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

(Rajesh Mahajan)

Managing Director

DIN No.: 02000634

